Prometheus Biosciences, Inc. (RXDX) Financial Statements (2024 and earlier)

Company Profile

Business Address 3050 SCIENCE PARK ROAD
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2023
Q3
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
9/30/2021
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments695,752260,248211,782227,034257,254279,116
Cash and cash equivalents292,42378,41395,959227,034257,254279,116
Short-term investments403,329181,835115,823   
Receivables 1,0299411,8651,2881,079679
Prepaid expense2,2062,2302,2012,6791,2181,552
Other undisclosed current assets9,1642,6373,5023,9835,8325,761
Total current assets:708,151266,056219,350234,984265,383287,108
Noncurrent Assets
Operating lease, right-of-use asset27,77428,21714,37714,608  
Property, plant and equipment3,8773,3742,8912,4531,4471,362
Other undisclosed noncurrent assets9719719711,536971468
Total noncurrent assets:32,62232,56218,23918,5972,4181,830
TOTAL ASSETS:740,773298,618237,589253,581267,801288,938
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,29711,9186,6084,1746,9875,455
Employee-related liabilities4,9362,8541,6165,3783,311
Accounts payable7621,0784621,8121,1531,663
Accrued liabilities5,5355,9043,292746456481
Deferred revenue1,2981,5441,7812,1323,6683,561
Disposal group, including discontinued operation  157110385193475
Other undisclosed current liabilities15,22210,1607,96810,6335,5945,602
Total current liabilities:22,81723,77916,46717,32416,44215,093
Noncurrent Liabilities
Long-term debt and lease obligation:  26,66313,55813,732  
Liabilities, other than long-term debt41,98815,64115,73315,80216,20411,745
Deferred revenue15,66715,64115,73315,80216,20411,745
Operating lease, liability26,32126,66313,55813,732  
Total noncurrent liabilities:41,98842,30429,29129,53416,20411,745
Total liabilities:64,80566,08345,75846,85832,64626,838
Equity
Equity, attributable to parent675,968232,535191,831206,723235,155262,100
Common stock544444
Additional paid in capital1,007,485525,311447,191428,126424,492421,519
Accumulated other comprehensive loss(429)(451)(310)   
Accumulated deficit(331,093)(292,329)(255,054)(221,407)(189,341)(159,423)
Total equity:675,968232,535191,831206,723235,155262,100
TOTAL LIABILITIES AND EQUITY:740,773298,618237,589253,581267,801288,938

Income Statement (P&L) ($ in thousands)

3/31/2023
Q3
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
9/30/2021
Q3
Revenues6539681,2693,9191,0371,006
Gross profit:6539681,2693,9191,0371,006
Operating expenses(41,983)(39,351)(35,237)(36,015)(30,981)(27,799)
Operating loss:(41,330)(38,383)(33,968)(32,096)(29,944)(26,793)
Nonoperating income (expense)2,5661,1083213026(540)
Investment income, nonoperating2,5661,108321302627
Interest and debt expense      (554)
Loss from continuing operations:(38,764)(37,275)(33,647)(32,066)(29,918)(27,887)
Loss before gain (loss) on sale of properties:(37,275)(33,647)(32,066)(29,918)(27,887)
Net loss:(38,764)(37,275)(33,647)(32,066)(29,918)(27,887)
Other undisclosed net income attributable to parent      554
Net loss available to common stockholders, diluted:(38,764)(37,275)(33,647)(32,066)(29,918)(27,333)

Comprehensive Income ($ in thousands)

3/31/2023
Q3
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
9/30/2021
Q3
Net loss:(38,764)(37,275)(33,647)(32,066)(29,918)(27,887)
Comprehensive loss:(38,764)(37,275)(33,647)(32,066)(29,918)(27,887)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent22(141)(310)   
Comprehensive loss, net of tax, attributable to parent:(38,742)(37,416)(33,957)(32,066)(29,918)(27,887)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: